Drug Profile
Oportuzumab monatox - Carisma Therapeutics
Alternative Names: 4D5MOCB-ETA; Anti-ECAM exotoxin A fusion protein; oportuzumab monatox-qqrs; Proxinium; VB-4847; VB-845; VB4-845; Vicineum; VysyneumLatest Information Update: 29 Mar 2023
Price :
$50
*
At a glance
- Originator University of Zurich
- Developer Carisma Therapeutics; National Cancer Institute (USA); Qilu Pharmaceutical; Viventia Biotechnologies
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Bladder cancer; Head and neck cancer
- Discontinued Liver cancer; Ovarian cancer
Most Recent Events
- 07 Mar 2023 Sesen Bio has merged with Carisma Therapeutics to form Carisma Therapeutics
- 02 Mar 2023 Suspended - Phase-II for Bladder cancer in Canada (Intravesicular)
- 02 Mar 2023 Suspended - Phase-III for Bladder cancer (Late-stage disease, Second-line therapy or greater) in Canada (Intravesicular)